公开(公告)号：US20240301501A1

公开(公告)日：2024-09-12

申请号：US18281523

申请日：2022-03-11

申请人： AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH ,  NALAGENETICS PTE. LTD.

发明人： Alexander Lezhava ,  Astrid Irwanto ,  Kanika Jain ,  Anar Sanjaykumar Kothary ,  Jocelyn Tan ,  Flona Ng ,  Zhihao Tan

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The invention relates to a method for assessing and evaluating the potential effect of therapeutics on an individual. In particular, the invention uses real-time PCR-based pharmacogenomic assays in assessing such potential effects. In an aspect of the present invention, there is provided a method of assessing or evaluating a subject's likelihood of developing an adverse reaction in response to an administration of a therapeutic agent, or a method of assessing or evaluating a therapeutic agent's efficacy on a subject, the method comprising determining in a single real-time polymerase chain reaction run the presence of a variant in a set of genes consisting of CYP2D6, CYP2C9, CYP2C19 and SLCO1B1 in a sample obtained from the subject, wherein the presence of a variant on any one of the genes in the set of genes is indicative of a risk to an adverse reaction and/or a change in efficacy to the therapeutic agent.